Om P. Ganda, M.D.
Dr. Ganda is a board-certified specialist in Internal Medicine, Endocrinology and Metabolism, and Clinical Nutrition, a Senior Physician in the Section on Adult Diabetes at Joslin, and an Associate Clinical Professor of Medicine at Harvard Medical School. Dr. Ganda received his medical degree from the S. M. S. Medical College of the University of Rajasthan in Jaipur, India, and completed a rotating internship at the S. M. S. Hospital. He completed a residency in medicine at the All India Institute of Medical Science in New Delhi, and a residency in medicine at Tufts University School of Medicine. Dr. Ganda subsequently completed a clinical fellowship in Endocrinology and Metabolism at Tufts University and a research fellowship in medicine at Harvard Medical School.
A Co-Investigator in the landmark Diabetes Control and Complications Trial (DCCT), completed in 1983, Dr. Ganda has been engaged in clinical diabetes research for more than three decades. The DCCT demonstrated the importance of glucose control in preventing complications in type 1 diabetes. Dr. Ganda is now Co-Investigator of Epidemiology of Diabetes Intervention and Complications (EDIC), an ongoing long-term follow-up study.
In earlier clinical research, Dr. Ganda studied insulin secretion in undiagnosed people genetically at risk of type 1 or type 2 diabetes because they had parents or an identical twin with the disease. He contributed to the observationthat autoimmune attacks on insulin-producing beta cells actually begin years before clinical symptoms lead to a definitive diagnosis.
Dr. Ganda was also a Co-Investigator of the Diabetes Prevention Program, which found that both lifestyle changes and medication dramatically reduced progression to type 2 diabetes in people with obesity or a family history of risk factors. Diet and exercise alone reduced the progression by 58 percent.
In addition to his clinical research and teaching, Dr. Ganda directs the Lipid Clinic at Joslin, where he treats patients with elevated cholesterol and triglycerides. He also studies why patients with type 2 diabetes have increased susceptibility to cardiovascular disease and elevated lipids. He is a Co-Investigator of several ongoing clinical trials to identify better medications for people who have difficulty with exercise and diet control. The goal is to find one pill that will control not only cholesterol and triglycerides (as statins do), but also blood pressure and blood glucose.
Ganda OP. Lipid management in diabetes. Clinical Diabetes: Translating Research into Practice. Fonseca VA (ed). Philadelphia: Saunders-Elsevier, pp. 343-353, 2006.
Ganda OP. Secondary forms of diabetes. Joslin’s Diabetes Mellitus. 14th edition. Kahn CR, Weir GC, King GL, Jacobson AM, Moses AC, Smith RJ (eds). Philadelphia: Lea and Febiger, pp. 477-492, 2005.